secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2024-09-13T23:59:59+00:00
Accession:  0000950170-24-106362
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude reports Phase 1 interim data: PRT3789 shows 3 confirmed PRs in NSCLC/esophageal, well tolerated
--------------------------------------------------------------------------------

- 3 confirmed partial responses in 2 esophageal and 1 NSCLC patient out of 26 evaluable; 7 patients had tumor shrinkage.
- PRT3789 was well tolerated in 65 patients; no dose-limiting toxicities or drug-related serious adverse events.
- Dose escalation continues to cohort 9 (500 mg once weekly); MTD not yet reached.
- Company expects to confirm biologically active dose as monotherapy by year-end.
- Data presented at ESMO 2024; also selected for plenary session at EORTC-NCI-AACR Symposium in October 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000095017024106362/0000950170-24-106362-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000095017024106362/prld-20240913.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-106362

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer